Peer-reviewed veterinary case report
Long-term survival in dogs with stage 4 oral melanoma after anti-PD-1
By M. Igase et al.·Published in Veterinary and Comparative Oncology·2022·View original on Semantic Scholar →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Long-term survival of dogs with stage 4 oral malignant melanoma treated with anti-canine PD-1 therapeutic antibody: a follow-up case report.
- Species:
- dog
Plain-English summary
A dog with stage 4 oral malignant melanoma (a type of mouth cancer) was treated with a new antibody therapy designed to help the immune system fight cancer. After treatment, both dogs showed long-term survival and complete disappearance of their tumors, although one dog took longer to respond than the other. Even after stopping treatment, one dog continued to show positive results for over a year. However, both dogs developed secondary tumors during their treatment. This promising therapy may change how we evaluate cancer treatment responses in dogs.
People also search for: dog mouth cancer treatment · oral melanoma in dogs · PD-1 therapy for dogs
Abstract
A monoclonal antibody targeting programmed cell death-1 (PD-1) is one of the most promising treatments for human cancers. Clinical studies in humans demonstrated that the anti-PD-1 antibody provides a long-lasting tumor response. Previously, we established an anti-canine PD-1 therapeutic antibody (ca-4F12-E6), and the pilot clinical study demonstrated that the antibody was effective in dogs with oral malignant melanoma (OMM). However, two OMM cases were still undergoing treatment when the pilot study was published. Here, we describe the long-term follow-up of those two cases. Although both cases showed long-term survival with complete response (CR), the tumor response differed; the effect onset was slow in one case and a durable response was observed in the second case even after treatment discontinuation. Secondary malignant tumors occurred during treatment in both cases. This follow-up study revealed that ca-4F12-E6 maintains CR in dogs for more than 1 year. In addition, the pattern of tumor response was unique compared to conventional therapy. These results indicate that new evaluation criteria for tumor response may be necessary for immunotherapy in veterinary medicine. Long-term follow-up is necessary regardless of the short-term treatment responsiveness.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on Semantic Scholar: https://www.semanticscholar.org/paper/35535636